Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the IMAPA study.
Lyn D FergusonSusanne CathcartDominic RimmerGary SempleKatriona BrooksbankCaron PatersonRosemary BrownJohn HarvieXuan GaoAleksandra RadjenovicPaul WelshIain B McInnesNaveed SattarStefan SiebertPublished in: Rheumatology (Oxford, England) (2021)
Following apremilast treatment, we observed weight loss, principally abdominal subcutaneous fat, and improvement in psoriatic disease activity. The latter was independent of weight change, suggesting apremilast likely acts through direct immunological mechanisms.
Keyphrases
- disease activity
- rheumatoid arthritis
- weight loss
- systemic lupus erythematosus
- ankylosing spondylitis
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- bariatric surgery
- roux en y gastric bypass
- body mass index
- gastric bypass
- physical activity
- obese patients
- metabolic syndrome
- fatty acid
- glycemic control